NXC736 is a novel small-molecule compound that targets Sphingosine-1 Phosphate (S1P) receptors, reducing lymphocyte migration from peripheral circulation to inflamed tissues, thereby exerting an immunosuppressive effect.
Unlike existing therapies that act non-selectively on S1P receptors, NXC736 selectively targets S1PR1 and S1PR4, leading to improved safety and reduced side effects.
In 2020, NXC736 was selected for the Advanced Medical Technology Development Program by the Korea Health Industry Development Institute (KHIDI) and successfully completed Phase 1 clinical trials. In 2024, it was chosen as a Phase 2 clinical trial project by the Korea Drug Development Fund (KDDF) and is currently in Phase 2 clinical trials.
| Indication | Alopecia Areata, Ulcerative Colitis |
|---|---|
| Route of Administration | Oral |
| Development Status | Phase II |
| Mechanism of Action | S1P Receptor 1&4 Selective Modulator |
| Highlight |
|
